https://socictopen.socict.org/files/original/3575937055efde49a0eef61b774d7d77.pdf 51088a2c7eaf3ec8ec7fcff6cba9629c Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Generation of a Nebulizable CDR-Modified MERS-CoV Neutralizing Human Antibody Creator An entity primarily responsible for making the resource Sang-il Kim, Sujeong Kim, Jin-Hee Kim, Soyoung Chang, Jung Min Shim, Jongwha Jin, Chungsu Lim, Songyi Baek, Ji-Young MIN, Wan Beom Park, Myoung-don Oh, Seungtaek Kim, Junho Chung Description An account of the resource Middle East respiratory syndrome coronavirus (MERS-CoV) induces severe aggravating respiratory failure in infected patients, frequently resulting in mechanical ventilation. As limited therapeutic antibody is accumulated in lung tissue following systemic administration, inhalation is newly recognized as an alternative, possibly better, route of therapeutic antibody for pulmonary diseases. The nebulization process, however, generates diverse physiological stresses, and thus, the therapeutic antibody must be resistant to these stresses, remain stable, and form minimal aggregates. We first isolated a MERS-CoV neutralizing antibody that is reactive to the receptor-binding domain (RBD) of spike (S) glycoprotein. To increase stability, we introduced mutations into the complementarity-determining regions (CDRs) of the antibody. In the HCDRs (excluding HCDR3) in this clone, two hydrophobic residues were replaced with Glu, two residues were replaced with Asp, and four residues were replaced with positively charged amino acids. In LCDRs, only two Leu residues were replaced with Val. These modifications successfully generated a clone with significantly greater stability and equivalent reactivity and neutralizing activity following nebulization compared to the original clone. In summary, we generated a MERS-CoV neutralizing human antibody that is reactive to recombinant MERS-CoV S RBD protein for delivery via a pulmonary route by introducing stabilizing mutations into five CDRs. Date A point or period of time associated with an event in the lifecycle of the resource 2019 Subject The topic of the resource MERS-CoV, Aerosol delivery, Nebulizer, neutralizing antibody, antibody engineering, Pulmonary disease, complementarity determining regions Identifier An unambiguous reference to the resource within a given context DOI: 10.3390/ijms20205073 Source A related resource from which the described resource is derived International Journal of Molecular Sciences Publisher An entity responsible for making the resource available MDPI AG Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Biology (General), Chemistry Language A language of the resource EN